Literature DB >> 15368295

Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs.

Jae Kyung Lee1, Kent S Boles, Porunelloor A Mathew.   

Abstract

CS1 (CRACC, novel Ly9) is a novel member of the CD2 family expressed on natural killer (NK), T and stimulated B cells. Although the cytoplasmic domain of CS1 contains immunoreceptor tyrosine-based switch motifs (ITSM), which enables to recruite signaling lymphocyte activation molecule (SLAM)-associated protein (SAP/SH2D1A), it activates NK cells in the absence of a functional SAP. CS1 is a self ligand and homophilic interaction of CS1 regulates NK cell cytolytic activity. Here we have identified a novel splice variant of CS1 (CS1-S), which lacks ITSM. Human NK cells express mRNA for both wild-type CS1 (CS1-L) and CS1-S and their expression level remained steady upon various stimulations. To determine the function of each isoform, cDNA for CS1-L and CS1-S were transfected into the rat NK cell line RNK-16 and functionally tested using redirected cytotoxicity assays and calcium flux experiments. CS1-L was able to mediate redirected cytotoxicity of P815 target cells in the presence of monoclonal antibody against CS1 and a rise in intracellular calcium within RNK-16 cells, suggesting that CS1-L is an activating receptor, whereas CS1-S showed no effects. Interestingly, SAP associated with unstimulated CS1-L and dissociated upon pervanadate stimulation. These results indicate that CS1-L and CS1-S may differentially regulate human NK cell functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15368295     DOI: 10.1002/eji.200424917

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  Human T cell leukemia virus type I tax-induced IκB-ζ modulates tax-dependent and tax-independent gene expression in T cells.

Authors:  Ryuichiro Kimura; Masachika Senba; Samuel J Cutler; Stephen J Ralph; Gutian Xiao; Naoki Mori
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

2.  An epistatic effect of the female specific loci on the development of autoimmune vasculitis and antinuclear autoantibody in murine lupus.

Authors:  M-C Zhang; N Misu; H Furukawa; Y Watanabe; M Terada; H Komori; T Miyazaki; M Nose; M Ono
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

3.  CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Authors:  Sara Yousef; Magdalena Kovacsovics-Bankowski; Mohamed E Salama; Neelam Bhardwaj; Mary Steinbach; Amanda Langemo; Tibor Kovacsovics; James Marvin; Mascha Binder; Jens Panse; Nicolaus Kröger; Tim Luetkens; Djordje Atanackovic
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus.

Authors:  J R Kim; S O Mathew; R K Patel; R M Pertusi; P A Mathew
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

Review 5.  Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.

Authors:  Hila Magen; Eli Muchtar
Journal:  Ther Adv Hematol       Date:  2016-06-10

6.  Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.

Authors:  Huaijian Guo; Mario-Ernesto Cruz-Munoz; Ning Wu; Michael Robbins; André Veillette
Journal:  Mol Cell Biol       Date:  2014-10-13       Impact factor: 4.272

7.  Alternative splicing and mRNA expression analysis of bovine SLAMF7 gene in healthy and mastitis mammary tissues.

Authors:  Zhihua Ju; Changfa Wang; Qiuling Li; Minghai Hou; Shuai Gao; Qinlei Hou; Jianbin Li; Jinming Huang; Jifeng Zhong
Journal:  Mol Biol Rep       Date:  2011-07-17       Impact factor: 2.316

Review 8.  CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Authors:  Joseph D Malaer; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

9.  B cell TLR7 expression drives anti-RNA autoantibody production and exacerbates disease in systemic lupus erythematosus-prone mice.

Authors:  Sun-Hee Hwang; Huiyin Lee; Miwako Yamamoto; Leigh A Jones; Jivanaah Dayalan; Richard Hopkins; Xin J Zhou; Felix Yarovinsky; John E Connolly; Maria A Curotto de Lafaille; Edward K Wakeland; Anna-Marie Fairhurst
Journal:  J Immunol       Date:  2012-11-12       Impact factor: 5.422

10.  Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.

Authors:  Jérôme Giustiniani; Armand Bensussan; Anne Marie-Cardine
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.